Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Irritable Colon Clear all
Completed Not applicable Interventional

Atrantil for Intestinal Bacterial Overgrowth

NCT04755673
View directory record Official record
Conditions
Irritable Bowel Syndrome, Bacterial Overgrowth Syndrome, SIBO
Interventions
Atrantil (Medical Food)
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Not applicable Interventional Results available

Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome

NCT00738920
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Self Administered Cognitive Behavior Therapy, Therapist Administered Cognitive Behavior Therapy, Behavioral Education and Supportive Therapy
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 70 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients

NCT03948854
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Registered dietitian, On-line video program, Printed handout, Dietitian-led group
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Phase 2 Interventional

A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

NCT01896583
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
ASP7147, Placebo
Drug
Lead sponsor
Seldar Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Encino, California • La Mesa, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients

NCT02078323
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 64 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Phase 2 Interventional

Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)

NCT00101985
View directory record Official record
Conditions
Irritable Colon
Interventions
talnetant
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
70
States / cities
Chandler, Arizona • Phoenix, Arizona • North Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Irritable Bowel Syndrome and Food Sensitivity

NCT02186743
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Personalized Dietary Advice
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

NCT04166058
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation, Functional Constipation
Interventions
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 18 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
65
States / cities
Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 22, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

NCT04043455
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Olorinab, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Jul 22, 2026, 1:27 AM EDT
Recruiting Phase 2 Interventional

The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT06211062
View directory record Official record
Conditions
ME/CFS, IBS - Irritable Bowel Syndrome
Interventions
Floradapt Intensive GI, Placebo
Drug · Other
Lead sponsor
Nova Southeastern University
Other
Eligibility
45 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Jul 22, 2026, 1:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders

NCT03266068
View directory record Official record
Conditions
Campylobacter Infections, Irritable Bowel Syndrome
Interventions
DNA Analysis of Blood Sample, Flexible sigmoidoscopy with colonic biopsies, Small bowel and colonic gastrointestinal permeability, Stool sample analysis
Genetic · Procedure · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)

NCT01253408
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Efficacy of Guided Imagery Therapy Mobile Application for Functional Abdominal Pain

NCT06653647
View directory record Official record
Conditions
Functional Abdominal Pain Disorders, Irritable Bowel Syndrome (IBS), Functional Gastrointestinal Disorders, Functional Colonic Disease, Gastrointestinal Disease, Digestive System Diseases, Neurological Manifestations, Signs and Symptoms, Digestive, Pain, Abdominal Pain/ Discomfort
Interventions
Guided Imagery Therapy
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 12 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jul 22, 2026, 1:27 AM EDT
Terminated Phase 1 Interventional

Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome

NCT00316550
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
AV608
Drug
Lead sponsor
Avera Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2008 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Not applicable Interventional Results available

Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation

NCT01162863
View directory record Official record
Conditions
Irritable Bowel Syndrome, Constipation
Interventions
Lubiprostone, Placebo, Smartpill wireless motility capsule
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease

NCT04879810
View directory record Official record
Conditions
Irritable Bowel Disease
Interventions
Sigmoidoscopy and biopsy, blood work
Procedure
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

NCT00731679
View directory record Official record
Conditions
Non-Constipation Irritable Bowel Syndrome
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
86
States / cities
Hueytown, Alabama • Phoenix, Arizona • Sierra Vista, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Jul 22, 2026, 1:27 AM EDT
Withdrawn Phase 1 Interventional

Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain

NCT01269671
View directory record Official record
Conditions
Functional Abdominal Pain, Irritable Bowel Syndrome, Functional Dyspepsia
Interventions
Melatonin, Peppermint Oil (mentharil), and Simethicone, Sugar pill
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 23, 2015 · Synced Jul 22, 2026, 1:27 AM EDT
Recruiting No phase listed Observational

Mucosal and Microbiota Changes During Acute Campylobacteriosis

NCT03223077
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Phase 2 Interventional

8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

NCT00230581
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DDP225
Drug
Lead sponsor
Dynogen Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Scottsdale, Arizona • St Louis, Missouri • Great Neck, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2007 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Phase 3 Interventional

Treatment of Functional Bowel Disorders

NCT00006157
View directory record Official record
Conditions
Irritable Bowel Syndrome, Constipation, Abdominal Pain, Functional Colonic Diseases
Interventions
Desipramine, Cognitive Behavioral Treatment
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

NCT01340053
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
RDX5791
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
San Diego, California • Jupiter, Florida • Pinellas Park, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Jul 22, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Endpoint Determination Study Protocol

NCT03459482
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Food Elimination Diet
Other
Lead sponsor
Biomerica
Industry
Eligibility
21 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Wauconda, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2024 · Synced Jul 22, 2026, 1:27 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Diet and Motility in IBS

NCT07283341
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
Wireless Patch System
Diagnostic Test
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 22, 2026, 1:27 AM EDT